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Abstract Apoptosis, a naturally occurring programmed cell
death or cell ‘suicide’, has been paid much attention as one of the
critical mechanisms for morphogenesis and tissue remodeling.
Activation of cysteine aspartases (caspases) is one of the critical
steps leading to apoptosis. Although a mitochondria-mediated
pathway has been postulated to be one of the activation
mechanism of caspase-3, another subcellular compartment might
be involved in the activation of the enzyme. The present study
shows that the supernatant fraction of digitonin-treated lyso-
somes strongly activates Ac-DEVD-CHO inhibitable caspase-3-
like protease. Activation of caspase-3-like protease by digitonin-
treated lysosomal fractions was specifically suppressed by
leupeptin and E-64, inhibitors of cysteine protease. These results
indicate that leakage of lysosomal cysteine protease(s) into the
cytosolic compartment might be involved in the activation of
caspase-3-like protease.
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1. Introduction
Apoptosis or programmed cell death plays important roles
in the regulation of tissue development and homeostasis [1,2].
In the last few years, many of the molecules that participate in
the biochemical pathway that mediates the highly ordered
process of apoptosis have been identi¢ed. A family of cysteine
proteases, the ‘caspases’, are at the heart of this pathway [3,4].
Among them, caspase-3 (DEVD-speci¢c CPP32) functions at
a late step of the protease cascade [5], and cleaves ‘death
substrates’, such as poly-ADP ribose polymerase (PARP)
and inhibitor of caspase-activated DNase (ICAD) [5,6].
Recent studies also revealed the involvement of mitochon-
dria in the activation pathway of caspase-3 [7,8]. Opening of
the permeability transition pore (PTP) of mitochondria in-
creases membrane permeability for low molecular weight
compounds, decreases the membrane potential, induces large
amplitude swelling, and releases cytochrome c (Cyt. c) [9]. In
the presence of dATP, caspase-3 is activated by an apoptotic
protease activating factor (Apaf) complex consisting of Apaf-
1 (human homolog of CED-4 protein), Apaf-2 (Cyt. c) and
Apaf-3 (pro-caspase 9) [9^11].
Recent studies also suggested that oxidative stress plays a
critical role in the mechanism of apoptosis [12^14]. Changes in
mitochondrial functions leading to energy depletion, increase
in cytosolic Ca2 level, thiol oxidation, lipid peroxidation and
DNA damage are also involved in the mechanism of apopto-
sis [15^18]. In this context, hydrogen peroxide-induced cellular
damage is often enhanced by the presence of a catalytically
active form of intracellular iron, leading to damage of lyso-
somal membranes and the release of their enzymes into the
cytosol [19^22]. Thus a mild increase in the permeability of
lysosomal membranes might possibly induce cellular changes
leading to apoptosis while extensive damage of the lysosomal
membranes might result in cellular swelling and necrosis
[19,20]. To test the possible involvement of lysosomal enzymes
in the mechanism of apoptosis, the e¡ects of digitonin, an
agent that disrupts membranes by reacting with cholesterol
[23], on the release of lysosomal enzymes and the activation
of caspases were investigated. The present work showed that
digitonin perturbed the lysosomal membrane and that the
released lysosomal enzymes activated caspase-3-like protease.
2. Materials and methods
2.1. Chemicals
Fluorogenic tetrapeptide substrates (Ac-YVAD-MCA, Ac-DEVD-
MCA), inhibitors of the caspase family (z-VAD-fmk, Ac-DEVD-
CHO) and inhibitor of cathepsin B (CA-074 Me) were obtained
from the Peptide Institute (Osaka, Japan). Various protease inhibitors
were obtained from Sigma Co. (St. Louis, MO, USA). All other
chemicals were of analytical grade and obtained from Nacalai Tesque
(Kyoto, Japan). Digitonin was dissolved in ethanol and used at ¢nal
ethanol concentrations lower than 0.5%.
2.2. Isolation of mitochondria and cytosolic fractions
After fasting overnight, liver mitochondria were isolated from Wis-
tar rats weighing 200^250 g by the method of Hogeboom [24]. A
cytosolic fraction of rat liver (S100) was obtained from a post-mito-
chondrial fraction of liver homogenate by centrifugation at
105 000Ug for 60 min. The samples were kept at 380‡C until use.
2.3. Puri¢cation of lysosomes
Rat liver lysosomes were isolated by a single two-phase partition on
dextran/polyethylene glycol by the method of Osada et al. [25].
Brie£y, a crude mitochondrial fraction was washed twice with 0.25
M sucrose at 4‡C and resuspended in a solution containing 0.32 M
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sorbitol, 0.1 mM EDTA and 5 mM ammonium phosphoric acid buf-
fer (pH 7.8) (SEAPB). The mixture was centrifuged at 19 000Ug for
20 min. The pellet was resuspended in SEAPB and superimposed on a
6.6% dextran T500/6.6% polyethylene glycol 40000 two-phase mixture
containing SEAPB. After centrifugation at 600Ug for 2 min, the
upper and lower phases, corresponding to lysosomal and mitochon-
drial fractions, respectively, were collected. The two fractions were
centrifuged at 19 000Ug for 30 min and washed with 0.25 M sucrose.
Highly puri¢ed lysosomes were also isolated from the liver of the
rat after administration of dextran one day before isolation by the
method of Arai et al. using a percoll density gradient centrifugation
[26].
2.4. Treatment of mitochondrial and lysosomal fractions by digitonin
and activation of caspase-3-like protease
Supernatants of crude mitochondrial and lysosomal fractions were
obtained by centrifugation at 20 000Ug for 10 min at 4‡C after treat-
ment of each fraction with 40 WM digitonin on ice for 10 min. To
determine whether the supernatant of digitonin-treated mitochondrial
and lysosomal fractions activate caspase-3-like protease, these super-
natants were incubated with S100 at 37‡C for 120 min. In some ex-
periments, various inhibitors were added to the reaction mixture.
2.5. Assay for enzymes
Activities of arylsulphatase and acid phosphatase were measured by
the method of Bergmeyer et al. [27]. N-acetyl-L-D-glucosaminidase
(NAGA) activity was assayed as described by Tarentino and Maley
[28]. After incubation with the supernatants of crude mitochondrial or
lysosomal fractions, caspase activity of S100 was assayed in 20 mM
HEPES bu¡er, pH 7.5, containing 0.1 M NaCl and 5 mM DTT at
37‡C for 60 min as described previously [29] using a 10 WM solution
of either Ac-YVAD-MCA (for caspase-1) or Ac-DEVD-MCA (for
caspase-3). Protein concentrations were determined by the method
of Lowry et al. [30] using bovine serum albumin as a standard.
3. Results and discussion
3.1. Activation of caspase-3-like protease by a crude
mitochondrial fraction
To test the activation of caspase-1- and 3-like proteases, a
supernatant of the digitonin-treated crude mitochondrial frac-
tion was incubated with rat liver cytosol (S100) for 120 min at
37‡C. Caspase-3- but not caspase-1-like protease in S100 was
strongly activated by the supernatant (Fig. 1). This activity
was inhibited by Ac-DEVD-CHO, a speci¢c inhibitor of cas-
pase-3. The activation of caspase-3-like protease was depen-
dent on the concentration of digitonin used for the treatment
of the crude mitochondrial fraction at 4‡C for 10 min (Fig.
2A); maximum activation was observed at a digitonin con-
centration of 80 WM. The activation of caspase-3-like protease
was dependent on the time of incubation with the supernatant
of crude mitochondrial fraction (Fig. 2B). Caspase-3-like pro-
tease was also activated by incubating cytosol with a super-
natant fraction of a freeze/thawed crude mitochondrial frac-
tion (data not shown). These results suggested that some
factors that activate caspase-3-like protease were released
from the crude mitochondrial fraction by digitonin treatment.
3.2. Inhibition of caspase-3-like protease activation by various
protease inhibitors
A crude mitochondrial fraction has been known to be con-
taminated with lysosomes. Because lysosomal membranes
contain cholesterol, digitonin might permeabilize those mem-
branes. In fact, activities of lysosomal enzymes are detected in
a supernatant of a crude mitochondrial fraction by treatment
with digitonin (Table 1). Activation of caspase-3-like protease
by the supernatant was inhibited by leupeptin and E-64, in-
hibitors of cysteine protease, but not by other inhibitors such
as PMSF, aprotinin and pepstatin A (Fig. 3). CA-074 Me [31],
a membrane permeable speci¢c inhibitor of cathepsin B which
is one of the major cysteine proteases in lysosome [32], also
had no inhibitory e¡ects on caspase-3-like protease activation,
indicating that cathepsin B is not involved in this activation.
Since caspase-3-like protease activity, once activated by the
supernatant, was not inhibited by leupeptin and E-64, these
inhibitors had no ability to inhibit caspase-3-like activity. In
contrast, caspase-3-like activity was inhibited by Ac-DEVD-
CHO, z-VAD-fmk and TPCK even if these inhibitors were
added after activation of caspase-3-like protease by the super-
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Fig. 1. E¡ect of a supernatant of a digitonin-treated mitochondrial
fraction on the activation of caspase-3-like protease. The mitochon-
drial supernatant was obtained by centrifugation at 20 000Ug for
10 min at 4‡C after treatment of the crude mitochondrial fraction
(1.5 mg protein/ml) with or without 40 WM digitonin on ice for
10 min. To activate caspase-3-like protease, 100 Wl of S100 (1 mg
protein/ml) was incubated with the 200 Wl supernatant of crude
mitochondrial fraction at 37‡C for 120 min. After incubation, the
mixture was incubated with 10 WM solution of £uorogenic peptide
substrate, Ac-YVAD-MCA (for caspase-1) or Ac-DEVD-MCA (for
caspase-3) in 20 mM HEPES medium containing 0.1 M NaCl,
5 mM DTT at 37‡C for 60 min. Data are the means þ S.D. from
three separate experiments.
Table 1
Activity of lysosomal enzymes in the supernatant of crude mitochondrial fraction, upper and lower phases of the two-phase partition of mito-
chondrial fraction, and highly puri¢ed lysosomal fraction after the treatment with digitonin
Enzyme activity (Wmol/min/ml extract)
Acid phosphatase Arylsulphatase NAGA
Crude mitochondrial fraction 10.62 þ 0.64 0.33 þ 0.10 30.86 þ 3.85
Two-phase partition
Lower phase (mitochondrial fraction) 2.06 þ 0.38 0.15 þ 0.06 12.43 þ 1.92
Upper phase (crude lysosomal fraction) 34.81 þ 14.45 0.84 þ 0.16 107.20 þ 43.33
Highly puri¢ed lysosomes 94.77 þ 26.20 3.92 þ 1.28 192.55 þ 13.03
Each fraction was treated with 40 WM digitonin. NAGA, N-acetyl-L-D-glucosaminidase; data are the means þ S.D. from three separate experiments.
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natant, indicating that these inhibitors directly inhibited cas-
pase-3-like activity (Fig. 3).
3.3. Caspase-3-like protease activation by digitonin-treated
lysosomes
To test the possible involvement of lysosomal enzymes in
the activation of caspase-3-like protease, we isolated a crude
lysosomal fraction from a rat liver homogenate using a single
two-phase partition on dextran/polyethylene glycol [25] and a
highly puri¢ed lysosome fraction using a percoll density gra-
dient centrifugation method [26]. Caspase-3-like protease was
strongly activated by the supernatant of a digitonin-treated
crude lysosomal fraction (upper phase) but not by a mito-
chondrial fraction (lower phase) (Fig. 4). In accordance with
the fact, much higher activities of lysosomal enzymes were
detected in the supernatant of upper phase than those of low-
er phase (Table 1). Furthermore, the ability of the supernatant
from puri¢ed lysosomes to activate caspase-3-like protease
was stronger than that from a crude lysosomal fraction (upper
phase) in parallel with the higher activities of lysosomal en-
zymes (Fig. 4 and Table 1).
Thus, the present work demonstrated for the ¢rst time that
the enzyme released from digitonin-treated lysosomes acti-
vated caspase-3-like protease and that the activation was spe-
ci¢cally inhibited by inhibitors of cysteine protease. Since a
speci¢c inhibitor against cathepsin B (CA-074 Me) did not
inhibit the activation, other lysosomal cysteine proteases
such as cathepsin L, cathepsin S, etc. [32] might be involved
in this activation.
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Fig. 3. E¡ect of protease inhibitors on the activation of caspase-3-
like protease by a supernatant of a digitonin-treated crude mito-
chondrial fraction. Experimental conditions were as described in
Fig. 1. Caspase-3-like protease in S100 was activated by the digito-
nin-treated supernatant of crude mitochondrial fraction for 120 min
at 37‡C. Inhibitors were added to the reaction mixture before or
after activation of caspase-3-like protease. Then caspase-3-like activ-
ity was measured in the presence of substrate. Concentrations of
z-VAD-fmk, Ac-DEVD-CHO, PMSF, TPCK, leupeptin, aprotinin,
E-64, CA-074 Me and pepstatin A were 30 WM, 30 WM, 0.1 WM,
30 WM, 10 Wg/ml, 10 Wg/ml, 10 WM, 10 WM and 10 Wg/ml, respec-
tively. White bar, control without inhibitors; shaded bars, inhibitors
were added after activation of caspase-3-like protease in S100 by
the supernatant; black bars, inhibitors were added before activation
of caspase-3-like protease in S100 by the supernatant. Data were ex-
pressed by % of control.
Fig. 4. Activation of caspase-3-like protease by digitonin-treated
crude and puri¢ed lysosomal fractions. Assay system for caspase-3-
like protease activation was as described in Fig. 1. A crude lysoso-
mal fraction (upper phase) was separated from mitochondrial frac-
tion (lower phase) by a single two-phase partition on dextrane/poly-
ethylene glycol [25]. Highly puri¢ed lysosomes were isolated using a
percoll density gradient centrifugation method [26]. Each fraction
(1.5 mg protein/ml) was treated with 40 WM digitonin and the
supernatants (200 Wl) were incubated with S100 (100 Wl). Data are
the means þ S.D. from three separate experiments.
Fig. 2. E¡ect of digitonin concentration and incubation time on the activation of caspase-3-like protease by the supernatant of a digitonin-
treated crude mitochondrial fraction. Experimental conditions were as described in Fig. 1. A: Dose-dependent curve of digitonin for the treat-
ment of crude mitochondrial fraction. The crude mitochondrial fraction was treated with various concentrations of digitonin for 10 min on ice.
B: Time-dependent curve for caspase-3-like protease activation by a digitonin-treated crude mitochondrial supernatant. S100 was incubated
with the supernatant of a digitonin (40 WM)-treated crude mitochondrial supernatant for the indicated time at 37‡C. Data are the means þ S.D.
from three separate experiments.
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Some proteases and endonucleases in lysosomes have been
reported to induce apoptosis of cells in the tadpole tail [33].
Apoptosis of cultured ¢broblasts and hepatocytes is also in-
duced by the photo-oxidative disruption of lysosomal mem-
branes [34] and by cathepsin B [35], respectively. Inositol-3-
phosphate (IP3) increased the intracellular concentration of
calcium ions and induced apoptosis in neuronal cells of mon-
keys through lysosomal enzymes activated by calpain [36] by a
leupeptin inhibitable mechanism [37]. Taken together, a mod-
erate release of enzymes from lysosomes into the cytosol
might activate caspase-3 and induce apoptosis of cells.
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